CD1d-NKT bispecific antibody

**CD1d-NKT bispecific antibody** most specifically refers to **1D12**, an experimental **single-domain bispecific antibody** that binds the human MHC class I-like antigen-presenting molecule **CD1d** while simultaneously engaging the **type I natural killer T cell receptor**, thereby stabilizing the CD1d-lipid-NKT TCR interaction and driving potent type I NKT-cell activation. In preclinical work, this VHH molecule enhanced NKT-cell-mediated antitumor activity in vitro, including in multiple myeloma and acute myeloid leukemia patient-derived bone marrow samples, and showed antitumor activity in vivo. It appears to be an academic-stage immuno-oncology program rather than a marketed therapeutic, with the published work associated with investigators including Hans van der Vliet, Jamie Rossjohn, and collaborators rather than a clearly identified commercial drug sponsor.

Other names

CD1d-NKT bispecific antibodyCD-1d-NKT bispecific antibodyCD 1d-NKT bispecific antibodyCD1d and the NKT T-cell receptor bispecific antibodyCD-1d and the NKT T-cell receptor bispecific antibodyCD 1d and the NKT T-cell receptor bispecific antibodyVHH1D12VHH-1D12VHH 1D12